Ten-Year Medicare Use and Spending on the 10 Drugs Selected for Negotiation Under the Inflation Reduction Act

被引：0
|
作者：
Essa, Mohammed [1 ,2 ]
Ross, Joseph S. [3 ,4 ]
Dhruva, Sanket S. [5 ]
Desai, Nihar R. [4 ,6 ]
Spatz, Erica S. [4 ,6 ]
Faridi, Kamil F. [4 ,6 ]
机构：
[1] Catholic Med Ctr, New England Heart & Vasc Inst, Manchester, NH USA
[2] Harvard TH Chan Sch Publ Hlth, Boston, MA USA
[3] Yale Sch Publ Hlth, Yale Sch Med, Dept Hlth Policy & Management, Sect Gen Internal Med,Dept Med, New Haven, CT USA
[4] Yale New Haven Hlth Syst, Ctr Outcomes Res & Evaluat, New Haven, CT USA
[5] Univ Calif San Francisco, Sch Med, Dept Med, Sect Cardiol, San Francisco, CA USA
[6] Yale New Haven Hlth Syst, Yale Sch Med, Ctr Outcomes Res & Evaluat, Sect Cardiovasc Med,Dept Internal Med, New Haven, CT USA
来源：
JOURNAL OF THE AMERICAN HEART ASSOCIATION | 2025年 / 14卷 / 03期
关键词：
cardiovascular diseases; drug costs; Medicaid; Medicare Part D; prescription drugs;
D O I：
10.1161/JAHA.124.034682
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 34 条
  • [1] MEDICARE UTILIZATION AND SPENDING ON THE 10 DRUGS SELECTED FOR NEGOTIATION UNDER THE INFLATION REDUCTION ACT
    Essa, Mohammed
    Desai, Nihar R.
    Dhruva, Sanket Shishir
    Ross, Joseph S.
    Spatz, Erica Sarah
    Faridi, Kamil
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2024, 83 (13) : 1896 - 1896
  • [2] Simulated Medicare Drug Price Negotiation Under the Inflation Reduction Act of 2022
    Rome, Benjamin N.
    Nagar, Sarosh
    Egilman, Alexander C.
    Wang, Junyi
    Feldman, William B.
    Kesselheim, Aaron S.
    JAMA HEALTH FORUM, 2023, 4 (01): : E225218
  • [3] INFLATION REDUCTION ACT: HOW WILL THE FIRST 10 DRUGS SELECTED FOR MEDICARE PRICE NEGOTIATIONS IMPACT US COMMERCIAL PAYERS?
    Sidhu, C.
    Connelly, B.
    Waththuhewa, M.
    Sullivan, N.
    VALUE IN HEALTH, 2024, 27 (06) : S197 - S197
  • [4] Medicare price negotiation and pharmaceutical innovation following the Inflation Reduction Act
    Vogel, Matthew
    Kakani, Pragya
    Chandra, Amitabh
    Conti, Rena M.
    NATURE BIOTECHNOLOGY, 2024, 42 (03) : 406 - 412
  • [5] Medicare price negotiation and pharmaceutical innovation following the Inflation Reduction Act
    Matthew Vogel
    Pragya Kakani
    Amitabh Chandra
    Rena M. Conti
    Nature Biotechnology, 2024, 42 : 406 - 412
  • [6] THE INFLATION REDUCTION ACT WILL CHANGE WHO PAYS FOR CARDIOVASCULAR DRUGS UNDER MEDICARE PART D
    Kazi, Dhruv
    DeJong, Colette
    Chen, Randi
    Tseng, Chien-Wen
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2023, 81 (08) : 1671 - 1671
  • [7] STRATEGIC IMPLICATIONS FOR BIOPHARMACEUTICALS: NAVIGATING THE MEDICARE PRICE NEGOTIATION PROVISIONS OF THE INFLATION REDUCTION ACT
    Briggs, S.
    Marder, T.
    Iyer, S.
    Francois, C.
    VALUE IN HEALTH, 2024, 27 (06) : S211 - S211
  • [8] TRENDS IN MEDICARE PART D SPENDING ON MIRABEGRON AND IMPLICATIONS OF THE INFLATION REDUCTION ACT OF 2022
    Berk, Brittany
    Dielubanza, Elodi
    Hwang, Thomas
    JOURNAL OF UROLOGY, 2023, 209 : E415 - E415
  • [9] Pharmaceutical Spending in Fee-for-Service Medicare Looking Ahead to the Inflation Reduction Act
    Gellad, Walid F.
    Hernandez, Inmaculada
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2022, 328 (15): : 1502 - 1503
  • [10] EVALUATING HEALTHCARE COSTS AND DEMOGRAPHICS OF MEDICARE PART D BENEFICIARIES IMPACTED BY FIRST TOP 10 DRUGS SELECTED FOR PRICE NEGOTIATIONS UNDER THE INFLATION REDUCTION ACT (IRA)
    Varghese, I
    Celli, J.
    Kardel, P.
    Liu, Z.
    Sheetz, C.
    VALUE IN HEALTH, 2024, 27 (06) : S348 - S348
1234